T 0655/24 concerns Genmab’s patent EP2943507 disclosing an antibody with an engineered triple Fc region mutation (L234F/L235E/D265A) – the “FEA”…
Read More
Filter By
To amend or not to amend? That was the question.
Further to our previous article, the Enlarged Board of Appeal (EBA) of the European Patent Office (EPO) has just issued…
Read More
UPC Court of Appeal adopts a ‘holistic’ approach to assessing inventive step in Amgen v Sanofi
In a significant judgment handed down in respect of Amgen’s European Patent EP3666797, which is a member of a patent…
Read More
No appeals without a party: EPO decides interveners cannot continue appeals alone
On 25 September 2025, the EPO’s Enlarged Board of Appeal (‘EBoA’) issued its decision in case G 2/24, the third…
Read More
Does the description matter when the patent has been granted?
The European Patent Office (EPO) does not give the description in a granted patent much weight when construing the claims….
Read More
Looking forward to the Emotional Perception Appeal Hearing? We certainly are
Last week the UK Intellectual Property Office (UKIPO) filed its grounds of appeal in the Emotional Perception appeal (Comptroller-General of Patents,…
Read More